BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.

Taylor L HickmanEugene ChoiKathleen R WhitemanSujatha MuralidharanTapasya PaiTyler JohnsonAvani ParikhTaylor FriedmanMadaline GilbertBinzhang ShenLuke BarronKathleen E McGinnessSeth A EttenbergGreg T MotzGlen J WeissAmy Jensen-Smith

Published in: PloS one (2022)

Together, these results demonstrated that co-expression of GOT2 can substantially improve the overall antitumor activity of CAR T cells by inducing broad changes in cellular function and phenotype. These data show that BOXR1030 is an attractive approach to targeting select solid tumors. To this end, BOXR1030 will be explored in the clinic to assess safety, dose-finding, and preliminary efficacy (NCT05120271).

Keyphrases

poor prognosis
primary care
binding protein
cancer therapy
big data
drug delivery
data analysis
artificial intelligence